Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more
Market Cap & Net Worth: Seoulin Bioscience Co.Ltd (038070)
Seoulin Bioscience Co.Ltd (KQ:038070) has a market capitalization of $39.79 Million (₩58.26 Billion) as of March 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #23980 globally and #1334 in its home market, demonstrating a 8.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Seoulin Bioscience Co.Ltd's stock price ₩6600.00 by its total outstanding shares 8826833 (8.83 Million).
Seoulin Bioscience Co.Ltd Market Cap History: 2015 to 2026
Seoulin Bioscience Co.Ltd's market capitalization history from 2015 to 2026. Data shows change from $61.41 Million to $39.79 Million (-4.48% CAGR).
Index Memberships
Seoulin Bioscience Co.Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.02% | #663 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.02% | #663 of 1384 |
Weight: Seoulin Bioscience Co.Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Seoulin Bioscience Co.Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Seoulin Bioscience Co.Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Seoulin Bioscience Co.Ltd's market cap is 0.00 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.01x
Seoulin Bioscience Co.Ltd's market cap is 0.01 times its annual earnings
0.11x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $61.41 Million | $41.63 Billion | $1.83 Billion | 0.00x | 0.03x |
| 2016 | $63.80 Million | $44.89 Billion | $4.07 Billion | 0.00x | 0.02x |
| 2017 | $52.61 Million | $42.62 Billion | $2.06 Billion | 0.00x | 0.03x |
| 2018 | $49.72 Million | $49.88 Billion | $2.62 Billion | 0.00x | 0.02x |
| 2019 | $45.89 Million | $54.41 Billion | $8.88 Billion | 0.00x | 0.01x |
| 2020 | $73.20 Million | $65.09 Billion | $4.89 Billion | 0.00x | 0.01x |
| 2021 | $119.69 Million | $80.54 Billion | $15.59 Billion | 0.00x | 0.01x |
| 2022 | $67.63 Million | $104.71 Billion | $10.16 Billion | 0.00x | 0.01x |
| 2023 | $55.46 Million | $89.57 Billion | -$117.55 Million | 0.00x | N/A |
| 2024 | $42.86 Million | $75.41 Billion | $2.91 Billion | 0.00x | 0.01x |
Competitor Companies of 038070 by Market Capitalization
Companies near Seoulin Bioscience Co.Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Seoulin Bioscience Co.Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Seoulin Bioscience Co.Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Seoulin Bioscience Co.Ltd's market cap moved from $61.41 Million to $ 39.79 Million, with a yearly change of -4.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩39.79 Million | +1.38% |
| 2025 | ₩39.25 Million | -8.44% |
| 2024 | ₩42.86 Million | -22.72% |
| 2023 | ₩55.46 Million | -18.00% |
| 2022 | ₩67.63 Million | -43.49% |
| 2021 | ₩119.69 Million | +63.51% |
| 2020 | ₩73.20 Million | +59.51% |
| 2019 | ₩45.89 Million | -7.72% |
| 2018 | ₩49.72 Million | -5.48% |
| 2017 | ₩52.61 Million | -17.54% |
| 2016 | ₩63.80 Million | +3.89% |
| 2015 | ₩61.41 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Seoulin Bioscience Co.Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $39.79 Million USD |
| MoneyControl | $39.79 Million USD |
| MarketWatch | $39.79 Million USD |
| marketcap.company | $39.79 Million USD |
| Reuters | $39.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.